NCT05688241View on ClinicalTrials.gov

EBV-Tscm Cytotoxic T Cells (CTLs) for EBV- Driven Lymphomas/ Diseases

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

November 30, 2026

Primary Completion Date

December 31, 2031

Study Completion Date

December 31, 2031

Conditions
EBV LymphomaPost-transplant Lymphoproliferative Disease (PTLD)
Interventions
DRUG

Donor-derived ex-vivo expanded EBV Tscm CTL

Cryopreserved cells will be thawed and infused at three time points. Dosing will be 2x10e6 EBV CTLs per kg of body weight. No prior lymphodepletion will be performed.

Trial Locations (8)

1011

Centre hospitalier universitaire vaudois, Service et Laboratoire central d'hématologie, Lausanne

1205

Hôpitaux Universitaires de Genève, Hôpital des Enfants, Geneva

1211

Hôpitaux Universitaires de Genève, Service d'Hématologie, Geneva

3010

Universitätsspital Bern, Klinik für Infektiologie, Bern

4031

University Hospital Basel, Klinik für Infektiologie und Spitalhygiene, Basel

4056

Universitäts-Kinderspital beider Basel (UKBB), Basel

8032

Kinderspital Zürich, Zurich

8091

University Hospital Zurich, Hämatologie, Zurich

All Listed Sponsors
lead

University Hospital, Basel, Switzerland

OTHER